stockrow
Friday 6 November 2026
Export LFCR’s income statement to Excel — free account
Lifecore Biomedical, Inc.
LFCR Healthcare Drug Manufacturers Specialty & Generic
Lifecore Biomedical, Inc.’s revenue for fiscal 2025 (year ended May 2025) was $128.9 million, roughly unchanged from fiscal 2024.
- Revenue
- −18.6%
- EPS
- −1,700.0%
- Free cash flow
- +27,684.0%
- Total debt
- +15.3%
Quarter to September 2026, against a year earlier
6.37
0.03
−0.47%
Follow LFCR
Alert me
Lifecore Biomedical, Inc. (LFCR) P/E ratio
Lifecore Biomedical, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 898× (August 2019) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 14.8× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 781× | 4,901.84% |
| FY2018 | 15.6× | (56.34%) |
| FY2017 | 35.8× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 45 more quarters | Free account |
Against its own ten years
Low 0.0×
High 898×
Ten-year median
0.0×
Current reading's percentile
65
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| EBS Emergent Biosolutions Inc. compare | n/m |
| SIGA Siga Technologies Inc. compare | n/m |
| ADCT ADC Therapeutics SA compare | n/m |
| BIOA BioAge Labs, Inc. compare | n/m |
| GLAS Glass House Brands Inc. compare | n/m |
| ANIK Anika Therapeutics Inc. compare | n/m |
| AKBA Akebia Therapeutics, Inc. compare | n/m |
| CGC Canopy Growth Corporation compare | n/m |
| LFCR Lifecore Biomedical, Inc. | n/m |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)